Limb-Girdle Muscular Dystrophy (LGMD)

Four New Biotechs Launch

Autoimmune Diseases, Digital Health, Financing, Investors, Limb-Girdle Muscular Dystrophy (LGMD), Metabolomics, Non-alcoholic steatohepatitis (NASH), Parkinson's Disease, Series A, Venture Capital

Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.

June 23, 2021/by Andrew Humphreys

Sarepta to buy Myonexus in gene therapy push

Acquisitions, Biotech, Business, Defective Cells, Gene Therapy, Genetics, Inherited Conditions, Limb-Girdle Muscular Dystrophy (LGMD), Viruses

Sarepta Therapeutics will buy privately held gene therapy company Myonexus Therapeutics for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.

February 27, 2019/by Reuters Health